PCR53 Patient Experiences Before and After Enfortumab Vedotin Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.1988
https://www.valueinhealthjournal.com/article/S1098-3015(22)04193-6/fulltext
Section Title :
Section Order :
11546
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)04193-6&doi=10.1016/j.jval.2022.09.1988